Vermillion Inc. announced that it has secured $10.5 million in new capital from a group of investment firms and company directors - and they have the option to purchase more shares of the struggling biotech company in mid-2015. The warrants for future stock could generate another $8.3 million for the company, which has pinned most of its business prospects on the OVA1 screening test for ovarian cancer.